Recent News

• 05.26.2026 - MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
• 04.27.2026 - New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
• 01.29.2026 - MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
• 12.01.2025 - Message from the CEO to MediciNova Shareholders

Recent Filings

• 05.14.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.29.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.29.2026 - ARS Annual Report to Security Holders
• 04.29.2026 - DEF 14A Other definitive proxy statements
• 04.20.2026 - PRER14A Preliminary Proxy Soliciting materials
• 04.17.2026 - PRE 14A Other preliminary proxy statements
• 03.10.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.20.2026 - EX-99.1 EX-99.1
• 02.20.2026 - 8-K Current report
• 01.20.2026 - 4 Statement of changes in beneficial ownership of securities